HSD17B家族与各种恶性肿瘤的预后和治疗预测有关;然而,与BLCA的关系尚不清楚。本研究旨在评估HSD17B1作为预后生物标志物的潜力,用于BLCA患者的生存,并确定其作为BLCA补充生物标志物的有效性。
应用一系列生物信息学技术来研究HSD17B1在不同类型癌症中的表达及其与BLCA患者预后的潜在关联。UALCAN,人类蛋白质图谱,cBioPortal,Metascape,GEPIA,MethSurv,和TIMER用于分析表达差异,突变状态,富集分析,总生存率,甲基化,和免疫浸润细胞。采用qRT-PCR检测HSD17B1的mRNA表达水平。
HSD17B1的mRNA和蛋白水平升高,超过正常水平,在BLCA样品中观察到。此外,HSD17B1mRNA表达水平较高的BLCA患者的OS明显降低。此外,几个免疫浸润细胞,包括肥大细胞restingCIBERSORT-ABS,已被确定为肿瘤相关的生物标志物基因,具有显著影响免疫环境的潜力。最后,qRT-PCR分析显示,与人293T细胞相比,癌细胞中HSD17B1mRNA表达水平显著上调,这与生物信息学数据一致。
在BLCA患者中,HSD17B1表达升高与阳性预后之间存在很强的相关性。因此,HSD17B1可用作这些患者的预后生物标志物。
The 17beta-hydroxysteroid dehydrogenase type 1 (HSD17B) family has been implicated in the prognosis and treatment prediction of various malignancies; however, its association with bladder cancer (BLCA) remains unclear. This study aimed to evaluate the potential of HSD17B1, as a prognostic biomarker, for the survival of patients with BLCA and to determine its effectiveness as a supplemental biomarker for BLCA.
A series of bioinformatics techniques were applied to investigate the expression of HSD17B1 in different types of cancer and its potential association with the prognosis of BLCA patients using diverse databases. The UALCAN, Human Protein Atlas, cBioPortal, Metascape, GEPIA, MethSurv, and TIMER were employed to analyze expression differences, mutation status, enrichment analysis, overall survival, methylation, and immune-infiltrating cells. The real-time reverse transcription-PCR (qRT-PCR) was implemented to detect the messenger ribonucleic acid (mRNA) expression levels of HSD17B1 in vitro.
Elevated mRNA and protein levels of HSD17B1, surpassing normal levels, were observed in BLCA samples. In addition, the BLCA patients with higher mRNA expression level of HSD17B1 significantly reduced the overall survival. Also, several immune infiltrating cells, including mast cell resting CIBERSORT-ABS, have been identified as tumor-associated biomarker genes, with the potential to significantly influence the immunological environment. Finally, qRT-PCR analysis revealed a significant upregulation of HSD17B1 mRNA expression level in the cancer cells compared to the human 293T cells, which was consistent with the bioinformatics data.
There is a strong correlation between the elevated HSD17B1 expression and positive prognosis in patients with BLCA. Therefore, HSD17B1 can be used as a prognostic biomarker in these patients.